@FiercePharma: Eli Lilly's 2013 profits forecast surpasses analyst predictions. What gives? More | Follow @FiercePharma
@AlisonBFierce: What's the buzz? Big Pharma may be on the verge of a buying spree. News | Follow @AlisonBFierce
> Cubist Pharmaceuticals ($CBST) boosted sales in 2012 by 23%, ending the year with $926.4 million in revenue, thanks to double-digit growth in sales of its Cubicin antibiotic. Report
> Bayer submitted its vision treatment VEGF Trap-Eye, sold as Eylea in the U.S., to Japanese regulators for approval in patients with a type of macular edema. Release
> Vivus ($VVUS) shares rose on news that the company shipped almost 13,000 prescriptions for its new weight-loss drug Qsymia for the four weeks ended Dec. 21. Report
> Dr. Reddy's, in the process of buying the Dutch drugmaker OctoPlus, bought up 80% of the company's shares for about 27.4 million euros. Report
> Malaysia is emerging as a major manufacturing hub for Indian pharmaceutical companies eager to expand their businesses in Southeast Asia. Report
> The Pentagon's soaring drug expenses could threaten national security, a report suggests. Report
@FierceMedDev: Johnson & Johnson's first vaginal mesh trial revs up this week. More | | Follow @FierceMedDev
@MarkHFierce: Illumina is grabbing Verinata Health for $350M-plus. The buy gets it into fetal Dx business. Story | Follow @MarkHFierce
@DamianFierce: Unregulated clinical trials are wreaking "havoc" in India, the supreme court says. News | Follow @DamianFierce
> SeraCare refocuses energies on in vitro Dx work. Item
> EndoChoice grabs $45M to back merger with Israeli GI startup. Story
Biotech News
@FierceBiotech: Indian supreme court: Unregulated trials causing 'havoc'. More | Follow @FierceBiotech
@JohnCFierce: As Big Pharma falters, Big Biotech helps fill a $100B "gap." Editor's Corner | Follow @JohnCFierce
@RyanMFierce: Boehringer doesn't want $LLY's basal insulin analog anymore, amends big diabetes pact. News | Follow @RyanMFierce
> Biotech buyout buzz swells as industry's dealmakers flock to JPMorgan confab. Story
> Gilead and biotech strike antibody deal worth north of $1.1B--maybe. News
> Cubist jumps on to Heptares' growing GPCR bandwagon. Article
Biotech IT News
> Quants collaborate on forecasting value of genomics in medicine. Story
> Is FDA keeping social media from taking flight in pharma? Editor's Corner
> Abbott spinoff AbbVie starts social media effort from scratch. Article
> Agilent unit picks up lab software rights to fuel cancer diagnostics biz. News
CRO News
> WCCT partners with U.S.'s largest trial registry on patient adherence. Article
> Questcor snags CMO BioVectra for $50.7M. News
> Cellular Dynamics signs on with AstraZeneca for drug discovery. Story
> Indian supreme court: Unregulated trials causing 'havoc'. Report
> Clinical Network Services buys CRO Beltas. Item
And Finally... Is the National Center for Drug Free Sport stringent enough to deter athletes from doping? Report (sub. req.)